NewAmsterdam Pharma Company N.V. (NAMSW) Operating margin 2022–2025
NewAmsterdam Pharma Company N.V. (NAMSW) operating margin by fiscal year — reported operating income divided by reported revenue.
-1002.9%FY2025 · since FY2022: -3.5% → -1002.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -1002.9% | -616.0 pp |
| FY2024 | -386.9% | +911.6 pp |
| FY2023 | -1298.6% | -1295.1 pp |
| FY2022 | -3.5% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMSW financial trends
NAMSW RevenueNAMSW Net incomeNAMSW Net marginNAMSW Gross profitNAMSW Gross marginNAMSW Operating incomeNAMSW Operating cash flowNAMSW Free cash flowNAMSW Capital expendituresNAMSW Return on equityNAMSW Stock buybacksNAMSW Dividends paidNAMSW Total assetsNAMSW Total liabilitiesNAMSW Shareholders’ equityNAMSW overview →